



CIN : L99999MH1951PLC008485

Regd. Office : A-1601, Thane One, DIL Complex, Ghodbunder Road, Majiwada, Thane (West) 400 610, Maharashtra, India

Tel : +91-22-67980888 , ● Fax : +91-22-67980899 , ● Email : contact@dil.net , ● Website: www.dil.net

Ref: DIL:DIL/BSE/2018-19/F.No.:S-23/ DE05

November 13, 2018

**Corporate Relations
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001**

Dear Sir,

Sub.: Intimation of Investor Release for November 2018

Ref: Scrip Code: 506414

Further to our intimation dated November 13, 2018 regarding approval of Unaudited Financial Results (Standalone and Consolidated) by the Board of Directors for the quarter and half year ended September 30, 2018, we hereby enclose a copy of Investor Release for November 2018.

The said Investor Release is also available on Company's website www.dil.net

Kindly take the same on records.

Thanking you,

Yours faithfully,
for **DIL LIMITED**

Srikant N Sharma
Company Secretary
CS Membership No: F3617
A-1601, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) 400610

Encl: As above

DIL LIMITED

Strong Momentum Continues in H1 FY19 Consolidated Financial Performance

- Total Revenue (including other income) up by 91% YoY to Rs. 214.02 Cr
- EBITDA (including other income) grew by 320% YoY to Rs. 82.92 Cr, margin is at 39%
- PAT grew by 1,820% YoY to Rs. 51.26 Cr

Mumbai – 13th November 2018




Results of Fermenta Biotech Limited, 91.2% Subsidiary of DIL Limited

Fermenta Biotech Limited (FBL) manufactures Vitamin D3 (Cholecalciferol), the only manufacturer and supplier in India and amongst the top few manufacturers in the world. Apart from Vitamin D3, it also manufactures niche APIs, and is a major supplier of Penicillin G Amidase, Polymer supports and Enzyme technologies for beta lactams and Bio-Enzymes for environmental solutions.

Revenue* (Rs. Crs)

EBITDA* (Rs. Crs)

PAT (Rs. Crs)



* Includes Other Income

Investor Release

Fermenta Biotech Limited							
Particulars (Rs. Crs)	Q2 FY19	Q2 FY18	YoY%	H1 FY19	H1 FY18	YoY%	FY18
Revenue*	126.52	65.25	94%	206.26	107.57	92%	300.48
EBITDA*	54.78	18.42	197%	83.45	22.65	268%	103.19
Margin (%)	43%	28%		40%	21%		34%
PAT	40.52	11.40	255%	61.62	12.53	392%	72.06
Margin (%)	32%	17%		30%	12%		24%

* Includes Other Income

- The revenue (including other income) stood at Rs. 206.26 Cr for H1 FY19 as against Rs. 107.57 Cr in H1 FY18 up by 92% YoY led by increase in volumes of Vitamin D3 segment and better realizations
- EBITDA margins stands at 40% for H1 FY19 as against 21 % in H1 FY18
- PAT for H1 FY19 stood at Rs. 61.62 Cr; growth of 392% YoY

Un-Audited Consolidated Results of DIL Ltd:

DIL Limited							
Particulars (Rs. Crs)	Q2 FY19	Q2 FY18	YoY%	H1 FY19	H1 FY18	YoY%	FY18
Revenue*	130.57	67.99	92%	214.02	112.10	91%	311.92
EBITDA*	53.75	17.71	203%	82.92	19.73	320%	101.96
Margin (%)	41%	26%		39%	18%		33%
PAT	34.58	6.38	442%	51.26	2.67	1,820%	54.84
Margin (%)	26%	9%		24%	2%		18%

* Includes Other Income

Commenting on the performance Mr. Satish Varma, Managing Director, Fermenta Biotech Limited said

“We are extremely pleased with our performance for H1 FY19. The business had gained momentum about a year ago and same has continued in this financial year.

Our core segment of Vitamin D3 has witnessed an overall growth of 90% in H1 FY19 on a YoY basis.

Delving further,

- Vitamin D3 (Humans) has witnessed a growth of 64% in H1 FY19 on a YoY basis. The prices of Vitamin D3 (Humans) have increased in comparison to H1 FY18
- Vitamin D3 (Feed) has witnessed a growth of 114% in H1 FY19 on a YoY basis

As the demand scenario for the Vitamin D3 has been constantly improving, we continue to invest in enhancing our manufacturing capacities. The improved demand for Vitamin D3 across the markets is on the back of increasing awareness of the importance of Vitamin D3.

Our concentrated efforts towards Enzyme manufacturing has started yielding results and has contributed to our profitability in H1 FY19. The total revenue in H1 FY19 from Enzyme business is Rs. 6.43 crores.

We believe the growth momentum will continue in volumes of Vitamin D3. With firming up of prices of Vitamin D3, along with growth in the Enzymes business, we are confident of achieving ~25% revenue growth for FY19.”

About DIL Ltd:

DIL holds 91.2% equity stake in Fermenta Biotech Limited (FBL), which was incorporated in 1986.

FBL is engaged in manufacturing of Vitamin D3, other specialty APIs, biological enzymes and also offers integrated biotech based environmental solutions. FBL has 2 manufacturing facilities:

- Kullu in Himachal Pradesh – cGMP certified and currently manufactures Vitamin D3, specialty API’s and Enzymes
- Dahej SEZ – set up in 2011 and manufactures Vitamin D3

DIL has developed premium office spaces named ‘THANE ONE’, with a total leasable area of 200,000 sq. ft., which is currently about 95% occupied.

For more information about the Company and its businesses, please visit our website www.dil.net

Safe Harbor Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further information, please contact

Company :

DIL Limited
CIN: L99999MH1951PLC008485
Mr. Sumesh Gandhi
sumesh.gandhi@dil.net

www.dil.net

Investor Relations Advisors :

Strategic Growth Advisors Pvt. Ltd.
CIN: U74140MH2010PTC204285
Mr. Rahul Agarwal
rahul.agarwal@sgapl.net
+91 79770 90416

www.sgapl.net